Noble Capital raised the firm’s price target on Ocugen (OCGN) to $12 from $8 and keeps an Outperform rating on the shares after the company reported Phase 2 data for OCU410, its gene therapy for geographic atrophy in dry age-related macular degeneration. The Phase 2 data shows “a significant clinical benefit that supercedes the two currently marketed GA drugs,” the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCGN:
- Ocugen price target raised to $10 from $7 at H.C. Wainwright
- Ocugen Reports Positive Phase 2 Data for OCU410 Therapy
- Midday Fly By: Estee Lauder in deal talks with Puig, Smithfield reports Q4 beat
- Ocugen announces 12-month data from ArMaDa clinical trial of OCU410
- TTD, OCGN, STZ, VRTX, LCID Trending With Analysts